Compare BridgeBio Pharma Inc (BBIO) vs Lam Research Corporation (LRCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Lam Research Corporation — how do they compare? BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B), while Lam Research Corporation trades at $325.44 (market cap $389.67B). The key difference: Lam Research Corporation is far larger — about 23.8× BridgeBio Pharma Inc's market cap, and Lam Research Corporation pays a 0.33% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | LRCX | |
|---|---|---|
Market Cap | $16.36B | $389.67B |
Sector | Health | Technology |
52-Week High | $90.17 | $433.33 |
52-Week Low | $47.29 | $97.03 |
Enterprise Value | $18.14B | $387.83B |
Dividend Yield | — | 0.33% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →
